Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 5/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ABL2 | P42684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048478 | 0.91 | METTL3 (0.35) | DOT1LCA2METTL3PRMT5SRC | |
| SCHEMBL30940989 | 0.91 | METTL3 (0.35) | DOT1LCA2METTL3PRMT5SRC | |
| SCHEMBL30941294 | 0.90 | METTL3 (0.34) | CA2METTL3PRMT5SRCABL1 | |
| SCHEMBL25049370 | 0.90 | SRC (0.35) | CA2SRCHPGDHTTABL1 | |
| SCHEMBL25048971 | 0.88 | CA2 (0.38) | CA2METTL3PRMT5SRCHPGD | |
| SCHEMBL25048580 | 0.82 | PRMT5 (0.32) | DOT1LCA2METTL3PRMT5 | |
| SCHEMBL25049371 | 0.81 | CA2 (0.34) | DOT1LCA2METTL3PRMT5 | |
| SCHEMBL25047887 | 0.80 | METTL3 (0.39) | METTL3PRMT5 | |
| Hydrochloric Acid SCHEMBL30940756 | 0.80 | METTL3 (0.39) | METTL3PRMT5 | |
| SCHEMBL25047886 | 0.80 | ABL1 (0.35) | CA2SRCABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | DOT1L 14/4885CA2 3376/4885METTL3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.